BeOne Medicines (ONC) Cash & Equivalents (2015 - 2026)
BeOne Medicines (ONC) reported Cash & Equivalents of $4.8 billion for Q1 2026, up 90.42% year-over-year from $2.5 billion in Q1 2025, and up 5.37% on a QoQ basis from $4.5 billion in Q4 2025.
BeOne Medicines (ONC) has 12 years of Cash & Equivalents data on file, last reported at $4.8 billion in Q1 2026.
- Quarterly Cash & Equivalents rose 90.42% year-over-year to $4.8 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.8 billion (up 90.42% YoY) and the FY2025 annual result came in at $4.5 billion, up 73.08% from the prior year.
- Cash & Equivalents climbed to $4.8 billion in Q1 2026 per ONC's latest filing, from $4.5 billion in the prior quarter.
- Across five years, Cash & Equivalents topped out at $4.8 billion in Q1 2026 and bottomed at $191000.0 in Q3 2022.
- The 5-year median for Cash & Equivalents is $3.1 billion (2023), against an average of $3.0 billion.
- The widest annual swing landed in 2022, when Cash & Equivalents slumped 99.99%; it then jumped 1605835.08% in 2023.
- Tracing ONC's Cash & Equivalents over 5 years: stood at $3.9 billion in 2022, then decreased by 18.03% to $3.2 billion in 2023, then slipped by 17.16% to $2.6 billion in 2024, then surged by 73.08% to $4.5 billion in 2025, then rose by 5.37% to $4.8 billion in 2026.
- Per Business Quant, the three latest ONC Cash & Equivalents figures stand at $4.8 billion (Q1 2026), $4.5 billion (Q4 2025), and $4.0 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 1.91 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | 32.30 Mn |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 901.90 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | 61.46 Mn |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 2.77 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 5.49 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 2.96 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | 18.44 Mn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 1.71 Bn |
| 10 | BeOne Medicines | - | - | 1.35 Bn | 4.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.79 Bn |
| Dec 31, 2025 | 4.55 Bn |
| Sep 30, 2025 | 4.04 Bn |
| Jun 30, 2025 | 2.76 Bn |
| Mar 31, 2025 | 2.52 Bn |
| Dec 31, 2024 | 2.63 Bn |
| Sep 30, 2024 | 2.70 Bn |
| Jun 30, 2024 | 2.59 Bn |
| Mar 31, 2024 | 2.79 Bn |
| Dec 31, 2023 | 3.17 Bn |
| Sep 30, 2023 | 3.07 Bn |
| Jun 30, 2023 | 3.41 Bn |
| Mar 31, 2023 | 3.54 Bn |
| Dec 31, 2022 | 3.87 Bn |
| Sep 30, 2022 | 191,000.00 |
| Jun 30, 2022 | 4.53 Bn |
| Mar 31, 2022 | 330,000.00 |
| Dec 31, 2021 | 328,000.00 |
| Sep 30, 2021 | 1.38 Bn |
| Jun 30, 2021 | 1.78 Bn |
| Mar 31, 2021 | 305,000.00 |
| Dec 31, 2020 | 1.38 Bn |
| Sep 30, 2020 | 1.46 Bn |
| Jun 30, 2020 | 283,000.00 |
| Mar 31, 2020 | 282,000.00 |
| Dec 31, 2019 | 618.01 Mn |
| Sep 30, 2019 | 14.27 Mn |
| Jun 30, 2019 | 14.57 Mn |
| Mar 31, 2019 | 14.90 Mn |
| Dec 31, 2018 | 14.54 Mn |
| Sep 30, 2018 | 14.56 Mn |
| Jun 30, 2018 | 438.42 Mn |
| Mar 31, 2018 | 17.46 Mn |
| Dec 31, 2017 | 239.60 Mn |
| Sep 30, 2017 | 208.51 Mn |
| Jun 30, 2017 | 261.01 Mn |
| Mar 31, 2017 | 97.75 Mn |
| Dec 31, 2016 | 87.51 Mn |
| Sep 30, 2016 | 85.53 Mn |
| Jun 30, 2016 | 58.08 Mn |
| Mar 31, 2016 | 208.51 Mn |
| Dec 31, 2015 | 17.87 Mn |
| Sep 30, 2015 | 27.45 Mn |
| Jun 30, 2015 | 25.16 Mn |
| Mar 31, 2015 | 13.37 Mn |